Last reviewed · How we verify

NPI-0052 on Days 1, 4, 8, 11 every 21 days

Celgene · Phase 1 active Small molecule Quality 0/100

NPI-0052 on Days 1, 4, 8, 11 every 21 days is a Small molecule drug developed by Celgene. It is currently in Phase 1 development. Also known as: marizomib, proteasome inhibitor.

At a glance

Generic nameNPI-0052 on Days 1, 4, 8, 11 every 21 days
Also known asmarizomib, proteasome inhibitor
SponsorCelgene
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about NPI-0052 on Days 1, 4, 8, 11 every 21 days

What is NPI-0052 on Days 1, 4, 8, 11 every 21 days?

NPI-0052 on Days 1, 4, 8, 11 every 21 days is a Small molecule drug developed by Celgene.

Who makes NPI-0052 on Days 1, 4, 8, 11 every 21 days?

NPI-0052 on Days 1, 4, 8, 11 every 21 days is developed by Celgene (see full Celgene pipeline at /company/celgene).

Is NPI-0052 on Days 1, 4, 8, 11 every 21 days also known as anything else?

NPI-0052 on Days 1, 4, 8, 11 every 21 days is also known as marizomib, proteasome inhibitor.

What development phase is NPI-0052 on Days 1, 4, 8, 11 every 21 days in?

NPI-0052 on Days 1, 4, 8, 11 every 21 days is in Phase 1.

Related